Indian pharma stocks experienced heavy selling on February 10, influenced by weak earnings and concerns over possible U.S.

Fears regarding the potential for US President Trump to impose tariffs on pharmaceutical imports suppressed pharma stocks ...

Indian pharma expected to grow at 9-10% in FY26, says Ind-Ra Ratings: Our Bureau, New Delhi Friday, February 7, 2025, 11:45 Hrs [IST] Credit rating firm India Ratings and Research ...

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, ...

India Inc anticipates simplified tax laws, reduced litigation, and progressive policies in Budget 2025, with the ...

While foreign investors have been reducing their exposure to Indian pharma, some leading domestic institutional investors ...

Piyush Goyal stresses the importance of innovation for the Indian pharmaceutical industry, warning that without it, the ...

With over thirty years experience in pharma Tapan Ray has a broad overview of how Indian pharma currently ... Technology cooperation with global pharmaceutical companies not only stimulates ...

Seven of India's top 10 most valued companies saw their market valuation ... Piyush Goyal stresses the importance of innovation for the Indian pharmaceutical... HCL Infosystems Narrows Q3 Loss to Rs 5 ...

This strategy enables Pfizer to maintain a strong foothold in the generic drug market while also protecting its revenue ...

The Indian Pharmaceuticals Market continued to deliver healthy growth at 8.7% year-on-year in January 2025, against 7.7% year ...

The Union Budget 2025 presents an opportunity to propel this sector toward innovation, self-reliance, and global leadership. The Pharma companies are seeking simplification and streamlining of ...